ΕΝΤΟΝΟΤΕΡΗ ΑΠΑΝΤΗΣΗ ΜΕ Τ-ΛΕΥΚΟΚΥΤΤΑΡΑ ΜΕΤΑ ΤΟΝ ΕΜΒΟΛΙΑΣΜΟ

Vaccination leads to higher T cell response in those previously infected with COVID-19 Rod Tucker 1 April, 2021 While evidence shows that a single COVID-19 vaccination dose elicits a higher antibody titre, the response of T-cells is less well defined. There are now several studies demonstrating that both the Pfizer-BioNTech or Oxford-AstraZeneca COVID-19 vaccines provide…

Read more

ΕΝΑ ΣΤΑ ΔΥΟ ΑΤΟΜΑ ΕΧΟΥΝ ΑΝΤΙΣΩΜΑΤΑ ΜΕΤΑ ΤΟΝ ΕΜΒΟΛΙΑΣΜΟ ΣΤΗΝ ΑΓΓΛΙΑ

od Tucker 1 April, 2021 With high rates of vaccination across the UK, the latest ONS data suggests that 1 in 2 people have COVID-19 antibodies. The Office for National Statistics (ONS) has been examining trends in the rate of infection with COVID-19 across the UK and separately, the proportion of individuals who have detectable…

Read more

ΜΕΤΑ ΤΟΝ ΕΜΒΟΛΙΑΣΜΟ ΜΠΟΡΕΙ ΤΟ ΤΕΣΤ ΑΝΤΙΓΟΝΟΥ ΓΙΑ COVID 19 ΝΑ ΕΙΝΑΙ ΘΕΤΙΚΟ ;

No. Neither the recently authorized and recommended vaccines nor the other COVID-19 vaccines currently in clinical trials in the United States can cause you to test positive on viral tests, which are used to see if you have a current infection.​ If your body develops an immune response—the goal of vaccination—there is a possibility you may test…

Read more

ΜΠΟΡΕΙ ΤΟ ΕΜΒΟΛΙΟ ΝΑ ΜΕ ΚΑΝΕΙ ΝΑ ΝΟΣΗΣΩ ;

No. None of the authorized and recommended COVID-19 vaccines or COVID-19 vaccines currently in development in the United States contain the live virus that causes COVID-19. This means that a COVID-19 vaccine cannot make you sick with COVID-19. There are several different types of vaccines in development. All of them teach our immune systems how to recognize…

Read more

ΜΕΤΑΛΑΞΗ SARS COV 2-ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑ ΕΜΒΟΛΙΟΥ PFIZER BIONTECH

n a small-scale study, researchers from the Department of Biochemistry and Molecular Biology, University of Texas, US, have tested antibodies generated by 20 patients given the BNT162b2 (i.e., the Pfizer vaccine) against a laboratory-developed isogenic COVID-19 variant that contained mutations in the N501 and Y501 regions and which is similar to the South African variant.…

Read more

ΛΙΠΩΔΕΣ ΗΠΑΡ ΣΥΝΟΨΗ ΣΥΝΕΔΡΙΟΥ

Παρακολουθώντας την διεξαγωγή διαδικτυακού συνεδρίου που έλαβε χώρα στην Βοστώνη στο πλαίσιο του Cardiometabolic health congress με συντονιστή τον Καθηγητή της Ιατρικής Σχολής Βοστώνης κύριο Χρήστο Μαντζώρο ,φάνηκε ποσο σημαντικό ειναι η διερεύνηση της ηπατικής συμμετοχής σε άτομα που πάσχουν απο σακχαρώδη διαβήτη τύπου 2,πολυκυστικές ωοθήκες ,αντίσταση στην ινσουλίνη, παχυσαρκία σε σχέση με την ανάπτυξη…

Read more

ΘΕΡΑΠΕΥΤΗΡΙΟ ΧΡΟΝΙΩΝ ΠΑΘΗΣΕΩΝ ΜΗΝΥΜΑ ΝΕΑΣ ΧΡΟΝΙΑΣ

Το Θεραπευτήριο Χρονίων Παθήσεων Δυτ. Αθήνας είναι μια μονάδα φιλοξενίας 160 περίπου ατόμων το οποίο ανήκει στο Κέντρο Κοινωνικής Πρόνοιας Περιφέρειας Αττικής και εποπτεύεται από το Υπουργείο Εργασίας. Η ιστορία του ιδρύματος αρχίζει το 1900 με το όνομα Κάνθαρος,πρώην στρατόπεδο,και στην συνέχεια αντιλεπρικός σταθμός ,τμήμα του Νοσοκομείου Λοιμωδών.Εκείνη την εποχή,επι Ελ. Βενιζέλου, είχαν προταθεί και…

Read more

Differences in immune and clotting functioning may explain less severe COVID-19 in children

Hospital Healthcare Europe 7 December, 2020   The lower incidence of severe COVID-19 in children has prompted much speculation. In reviewing various hypotheses, researchers believe that changes in endothelial cells and clotting functions is a likely reason for the disparity. A consistent finding of infection with COVID-19 is that the virus is less severe in children,…

Read more

Pregnant Women Should Be Offered COVID-19 Vaccine, Experts Agree

The Society for Maternal-Fetal Medicine recommends that pregnant and lactating women have access to COVID-19 vaccines in general and has advocated for the inclusion of women who are pregnant or lactating in vaccine trials. The society has suggested that health care professionals “counsel their patients that the theoretical risk of fetal harm from mRNA vaccines is…

Read more

MODERNA/PFIZER BIONTECH

Both Moderna’s vaccine — developed in collaboration with the U.S. National Institutes of Health — and Pfizer’s exceeded expectations in clinical trials. The comparable results are likely because the pair of COVID-19 vaccines are “a lot more alike than they are different,” says Susanna Naggie, an infectious disease physician at Duke University. “I think that’s…

Read more

Major Depression Linked to Insulin Resistance

individuals experiencing a current episode of major depressive disorder (MDD) are significantly more likely to have insulin resistance (IR), new research shows. Investigators found patients with MDD were 51% more likely to have IR compared with their counterparts without the depressive disorder. In addition, in individuals experiencing current depression, IR was also associated with depression…

Read more

Inactivated vaccines Inactivated vaccines have been in use since the 1880s. The viruses in these vaccines have been rendered inactive by chemical treatment, as with SARS-CoV-2 candidate vaccines, or by physical treatment. With this type of vaccine, the immune system encounters the virus in its entirety. It can mount a defence when it detects the viral spike protein (also called spicule or S-protein), envelope and nucleoprotein. Currently, seven inactivated vaccine candidates are being tested in humans. Of these, three are in Phase 3 clinical trials. Unlike Phase 1 and Phase 2, which are used to evaluate a vaccine’s tolerability, safety and ability to induce an immune response, a Phase 3 clinical trial allows scientists to test its efficacy. Recombinant proteins Recombinant protein vaccines fall into two categories: subunit and virus-like particle vaccines. For subunit protein vaccines, a viral protein is produced in large quantities in a living “factory,” such as a bacterium, plant, mammalian or insect cell. When the viral protein is presented to the immune system, it triggers a reaction. The 13 subunit vaccine candidates currently in Phase 1, 2 or 3 clinical trials are composed of either the entire spike protein or a specific portion of the spike protein called the ‘receptor binding domain’. Virus-like particle vaccines are composed of a set of viral proteins that mimic the shape of the virus. This particle “pseudo-virus” is an empty shell, devoid of genetic material and non-infectious, but this does not prevent the immune system from recognizing it. Viral vector vaccines This approach is based on using a virus that is non-pathogenic or of little danger to humans. In the case of the 12 vaccine candidates of this type currently being studied in humans, the viral vectors are mostly adenoviruses. They represent a large group of viruses that can cause colds and conjunctivitis, among other symptoms. Used as Trojan horses, these viruses are modified to express the SARS-CoV-2 spike protein following vaccination. Viral vector vaccines are a recent strategy, but were used in the development of the Ebola virus vaccine. RNA and DNA vaccines Despite differences in their composition, DNA and mRNA (messenger RNA) both contain genetic information for protein production. While an RNA molecule can directly produce that information, DNA requires an intermediate transcription step. RNA or DNA vaccine candidates differ from other strategies in two ways. First, it is a novel strategy: there is no RNA or DNA vaccine on the market. Second, they are the only vaccine candidates composed solely of genetic material. In the case of RNA vaccines, messenger RNA molecules are wrapped in lipid nanoparticles. Once the vaccine is injected, the RNA serves as a template for the body’s cells to produce a viral protein — the spike protein, to be precise. DNA vaccines, on the other hand, are made up of a circular DNA (called a plasmid). This DNA will be transcribed into RNA, which will again serve as a template. Six RNA vaccine candidates are currently being tested in humans, two of which are in Phase 3. The five DNA vaccine candidates are in Phase 1 and 2 clinical trials

Read more

Can Autoimmune Antibodies Explain Blood Clots in COVID-19?

Caption: Illustration showing a blood vessel with a platelet clot (yellow). Red blood cells (red), neutrophils (purple), and Y-shaped antibodies called aPL (white) circulate through the vessel. Credit: Stephanie King/Michigan Medicine For people with severe COVID-19, one of the most troubling complications is abnormal blood clotting that puts them at risk of having a debilitating…

Read more

Ορισμοί κρούσματος COVID-19 και «επαφών» κρούσματος COVID-19

Ορισμοί κρούσματος COVID -19 και «επαφών» κρούσματος COVID -19 Κλινικά κριτήρια Ασθενής με ένα τουλάχιστον από τα κατωτέρω συμπτώματα [1]: βήχας πυρετός δύσπνοια αιφνίδια εκδήλωση ανοσμίας, αγευσίας ή δυσγευσίας Απεικονιστικά διαγνωστικά κριτήρια Ακτινολογικά ευρήματα συμβατά με COVID-19 Εργαστηριακά κριτήρια Ανίχνευση νουκλεϊκού οξέος SARS-CoV-2 σε κλινικό δείγμα Επιδημιολογικά κριτήρια Τουλάχιστον ένα από τα κατωτέρω επιδημιολογικά κριτήρια: στενή…

Read more

ΣΤΡΑΤΗΓΙΚΗ ΛΗΞΗΣ ΚΑΡΑΝΤΙΝΑΣ ΚΑΙ ΑΠΟΜΟΝΩΣΗΣ ΣΤΕΝΩΝ ΕΠΑΦΩΝ & ΚΡΟΥΣΜΑΤΩΝ COVID19

ΣΤΡΑΤΗΓΙΚΗ ΛΗΞΗΣ ΚΑΡΑΝΤΙΝΑΣ ΚΑΙ ΑΠΟΜΟΝΩΣΗΣ ΣΤΕΝΩΝ ΕΠΑΦΩΝ & ΚΡΟΥΣΜΑΤΩΝ COVID19 Στο πλαίσιο της συνεχιζόμενης διασποράς του SARS-CoV-2, αυξάνοντας την ικανότητα ελέγχου σε διεθνές επίπεδο, και συγκεντρώνοντας στοιχεία σχετικά με την αποβολή του ιού και τη μολυσματικότητα του, υπάρχει ανάγκη επικαιροποίησης των οδηγιών για τον τερματισμό της απομόνωσης ατόμων με COVID-19. Οι οδηγίες αντικατοπτρίζουν τις διαθέσιμες…

Read more

Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients

In our study, the neutralizing antibody titer correlated with the severity of the disease. This result suggests that patients with more severe disease might be more protected against reinfection and those with asymptomatic or mild disease could be more vulnerable to waning immunity over time because the initial immune response was not as strong as…

Read more

Common SARS-CoV-2 Mutation May Be Making COVID-19 More Contagious

Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Most SARS-CoV-2 virus strains feature a specific mutation that makes them more transmissible, to the point that these strains now predominate globally, new evidence shows. In contrast to a greater variety of strains early in the pandemic, now 99.9% of circulating SARS-CoV-2 strains in…

Read more

Lilly”s Antibody Covid – 19

WPBakery Page Builder FDA Grants Emergency Use Authorization to Lilly’s Antibody COVID-19 Therapy       Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on Monday for the investigational monoclonal antibody therapy bamlanivimab (Eli Lilly) to…

Read more